Compare Star Bulk Carriers Corp (SBLK) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Star Bulk Carriers Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Star Bulk Carriers Corp trades at $29.7 (market cap $3.54B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 2.9× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays a 6.17% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Star Bulk Carriers Corp for 24 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SBLK | XBI | |
|---|---|---|
Market Cap | $3.54B | $10.11B |
Volume | 1,437,622 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $32.49 | $169.55 |
52-Week Low | $16.79 | $104.99 |
Typical Hold Time | 24 Days | 38 Days |
Enterprise Value | $4.22B | — |
Dividend Yield | 6.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Star Bulk Carriers (SBLK) trades at $30.47, up 2.63% today, with a bullish technical signal from moving averages and consistent earnings beats in recent quarters. The company reported strong Q2 2026 EPS of $1.21, exceeding expectations, and maintains a 100% free cash flow distribution policy, highlighted by a $0.90 dividend for H2 2026. Valuation metrics show a P/E of 11.95 and EV/EBITDA of 8.34, indicating reasonable pricing relative to earnings.
The outlook remains positive due to robust earnings growth, shareholder returns, and insider buying, but risks include shipping market volatility and reliance on global trade cycles. Analyst consensus is bullish with 14 buy ratings, supporting potential upside if operational momentum continues.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
